“In Catalonia, population density has large disparities in geographic distribution, with extensive rural areas with a very low population density. When EVT was introduced, at first the procedure was only performed in the Barcelona metropolitan area, covering approximately half of Catalonia's population, explained Dr Jordi Mayol. Patients living relatively far from Barcelona received less endovascular treatment and had worse time metrics and functional outcomes. Since then, centres performing EVT have been established in the more densely populated areas far from Barcelona.
Dr Mayol and colleagues set up a study to evaluate whether implementing stroke centres performing EVT in densely populated areas far from Barcelona could improve stroke care metrics [1]. This population-based study focused on outcomes of acute stroke patients within the catchment area of 3 primary stroke centres that transitioned to thrombectomy-capable centres. The proportion of patients treated with EVT and intravenous treatment (IVT), complete reperfusion, symptomatic intracranial haemorrhage (sICH) and time from ATP were compared before (Jan 2017 - June 2020) and after (July 2020 - December 2023). The 2 cohorts were matched with propensity score matching. The primary outcome was functional status assessed with mRS after 90 days.
The propensity score matching procedure retrieved 859 pairs. Patients had significantly better mRS in the post-implementation period after 90 days. The proportion of participants treated with EVT increased from 391 (67%) before the implementation to 471 (80.2%) after the implementation (OR 2.035; 95% CI 1.563–2.660; see figure), while patients treated with IVT decreased (OR 0.710; 95% CI: 0.564-0.893).
Figure: Proportion of vessel occlusions treated with thrombectomy [1]

There was a decrease in the time from first ATP and OTP of 65 and 45 minutes (95% CI 46-77, 17-75). Endovascular treatment was performed without a significant increase in symptomatic sICH and with similar rates of complete reperfusion.
- Mayol J. Clinical impact of endovascular treatment implementation in primary stroke centers of Catalonia. OPR-021, EAN Congress 2025, 21-24 June, Helsinki, Finland.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Influenza vaccine effectiveness in children shows moderate, broad protection during the 2024-2025 season »
« Letter from the Editor Next Article
Influenza vaccine effectiveness in children shows moderate, broad protection during the 2024-2025 season »
Table of Contents: EAN 2025
Featured articles
Letter from the Editor
Lecanemab in AD: not a paradigm shift, but a small step forward
Epilepsy
SUDEP is an underreported cause of death in epilepsy patients
Stroke
Significant impact of implementing thrombectomy in Spanish stroke centres
Sleep
OX2R agonists are a promising causal treatment of narcolepsy
Neurologists must wake up to the importance of sleep
Infectious Diseases
Virus-specific T cells show promise in treating PML
Parkinson's disease
Encouraging results of adaptive DBS for Parkinson’s disease
Cognitive Impairment and Dementia
Dementia doubles the mortality risk 1 year after hip fracture
Lecanemab in AD: not a paradigm shift, but a small step forward
Headache and Migrane
GLP-1R agonists reduce migraine burden in obese patients
Occipital nerve stimulation is no more effective than placebo in cluster headache
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Why a good result of migraine treatment may not be good enough
Multiple Sclerosis
Rituximab does not halt progression in non-active secondary progressive MS
Real-world data confirms the effectiveness and safety of ofatumumab in MS
Comparable effectiveness and persistence of ocrelizumab and natalizumab
Muscle/Neuromuscular Disorders
Earlier add-on treatment in myasthenia gravis improves outcomes
Long-term benefits of cipa/mig in late-onset Pompe disease
Neuropathies
Is ChatGPT helpful in diagnosing polyneuropathies?
Riliprubart could be a new treatment option for CIDP
CAR T cell therapy shows promise in severe autoimmune neuropathies
Related Articles
November 25, 2025
Caution is needed when discontinuing DMT in individuals under 60
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
